Comparison of 30-day Morbidity and Mortality in Cancer Patients Based on Emergency Department Location

NCT ID: NCT06834646

Last Updated: 2026-01-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-04-12

Study Completion Date

2026-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients being followed for cancer account for 2.8% of emergency admissions in France. An acute episode that triggers a visit to the emergency department may be related to the progression of the disease, or to complications of treatment. The management of these patients is often complex and requires a degree of expertise. Emergency departments specialising in the management of cancer complications have been set up, and now deal exclusively with patients treated at their centres. However, for geographical or logistical reasons, patients with cancer are likely to consult a non-specialist emergency department and/or one located outside the cancer care centre. In this case, the emergency doctor may not have access to the oncology file, and care in the emergency department and downstream services may be sub-optimal. Studies have shown a positive impact on the quality of care and prognosis of patients thanks to the cancer centre's expertise. However, the effect of the centre on a cancer patient who visits the emergency department has never been studied. This is particularly true if the emergency department where the patient is seen is located in the cancer follow-up centre.

The primary objective of the COVER study is to investigate the impact of the location of the emergency department where the patient is seen for their prognosis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer Cancer Remission

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients who visit the ED of the refereing oncologic hospital

No interventions assigned to this group

Patients who visit another ED

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients aged 18 or over admitted to an emergency department with cancer that has been active or in remission for less than a year.

Exclusion Criteria

\- Opposition to participate in the study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpital Pitié Salpêtrière Emergency department

Paris, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yonathan FREUND, PU-PH

Role: CONTACT

00 33 (0) 184827129

Olivier PEYRONY, MD, PhD

Role: CONTACT

00 33 (0) 142494939

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IDRCB: 2024-A01679-38

Identifier Type: OTHER

Identifier Source: secondary_id

APHP240971

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Supportive Oncology Care at Home Post-Discharge
NCT04637035 ACTIVE_NOT_RECRUITING NA